Anne Wojcicki’s non-profit gets court approval to buy 23andMe for US$305 million

A 23andMe saliva collection kit is shown on March 25, 2025, in Oakland, Calif. (AP Photo/Barbara Ortutay, File)

NEW YORK — Anne Wojcicki’s bid to buy 23andMe, the genetic testing company she co-founded nearly 20 years ago, has received the court greenlight.

That means Wojcicki’s non-profit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe’s assets for US$305 million. The transaction — which arrives more than three months after 23andMe filed for Chapter 11 bankruptcy — is set to officially close in the coming weeks.

“I am thrilled that TTAM will be able to build on the mission of 23andMe to help people access, understand and benefit from the human genome,” Wojcicki said in a statement Monday — later adding that, “the future of health care belongs to all of us.”

The sale, which was approved by U.S. Bankruptcy Judge Brian C. Walsh on Friday, marks the end of a months-long bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe’s assets for $256 million in May. But Wojcicki’s non-profit later topped that offer, winning the final round of bidding held last month.

Under the deal, TTAM will acquire 23andMe’s signature “Personal Genome Service” provided through the company’s saliva-based DNA testing kits — as well as research operations and its Lemonaid Health subsidiary, a telehealth services provider that 23andMe previously planned to wind down.

Wojcicki had worked to take 23andMe private for some time. With the company struggling to find a profitable business model since going public in 2021, she’s maintained that it would operate better outside market pressures. But that endeavour proved to be tumultuous — notably in September of last year, when all of 23andMe’s independent directors resigned from its board citing a “clear” difference of opinion with Wojcicki on the company’s future following drawn-out negotiations.

Leading up to 23andMe’s March bankruptcy filing, subsequent efforts from Wojcicki to acquire the company were unsuccessful. And when 23andMe filed for Chapter 11 in late March, Wojcicki resigned as CEO — noting at the time that she was stepping down to be “in the best position” as an independent bidder.

Now that Wojcicki’s nonprofit will acquire 23andMe, it’s unclear whether the co-founder will step back into the CEO seat. But despite stepping down from the top post months ago, Wojcicki has remained on the company’s board throughout the bankruptcy process.

Beyond financial strains leading up to 23andMe’s bankruptcy, privacy concerns related to customers’ genetic information also emerged — dating back to even before the bankruptcy process, notably with a 2023 data breach. But concern what new ownership could mean for 23andMe users’ personal data has bubbled up in recent months. The genetic testing business had about 13 million customers at the time of its sale hearing, court documents note.

In June, 27 states and the District of Columbia filed a lawsuit seeking to block the sale of personal genetic data by 23andMe without customer consent. And in a memorandum opinion outlining his approval 23andMe’s sale to TTAM on Friday, Walsh acknowledged these states’ objections to the acquisition — but that noted many had since been resolved. Still, California, Kentucky, Tennessee, Texas, and Utah “remain actively opposed to the sale.”

In a statement, California Attorney General Rob Bonta’s office maintained that 23andMe’s sale “does not comply” with genetic privacy law in the state — and said it was “disappointed” with the court’s approval.

“We are evaluating next steps and remain committed to protecting the data of Californians,” Bonta’s office added.

When announcing its intended sale to Wojcicki’s non-profit last month, 23andMe confirmed that TTAM “has affirmed its commitment” to comply with the company privacy policies and applicable law. That means TTAM will honor existing policies around consumer data, which includes allowing users to delete their data and “opt out” of research. The company added that TTAM will offer customers two years of Experian identity theft monitoring at no cost.

23andMe reiterated those privacy policies on Monday. And Wojcicki added that, “Core to my beliefs is that individuals should be empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish.”

23andMe also said that all customers would be emailed before the acquisition closes — with details on TTAM’s privacy commitments and instructions on how to delete data or opt out of research. Those emails appeared to begin going out on Tuesday, with a handful of consumers sharing images of the message online.

Wyatte Grantham-philips, The Associated Press